English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Protease inhibitors (PIs) are potent antiretroviral agents, although their rapid intestinal and hepatic metabolism, mainly by the cytochrome P450 pathway, leads to a low systemic exposure. Boosting PIs has had a significant impact on the treatment of type-1 human immunodeficiency virus (HIV-1) infection by improving their pharmacokinetic profile, resulting in more durable efficacy, higher barrier to resistance, reduced pill burden and dosing frequency [1]. Conclusion: Trough 48 weeks, switching DRV/RTV to DRV/COBI is safe and maintains viral efficacy, without significant changes in lipid profile or renal function.

Switching Darunavir/Ritonavir to Darunavir/Cobicistat in Clinical Practice Experience with 150 patients through 48 weeks